Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Cathie Wood's ARK ETFs made several strategic trades on October 9, 2026, significantly reducing its stake in DraftKings Inc. and CareDx, Inc. Concurrently, ARK increased its positions in gene-editing companies by purchasing shares of CRISPR Therapeutics AG, Guardant Health Inc., and Nurix Therapeutics, Inc., reflecting an ongoing interest in the biotech sector.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.